Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q5VW36
UPID:
FOCAD_HUMAN
Alternative names:
-
Alternative UPACC:
Q5VW36; D3DRJ9; Q6ZME1; Q8IZG0; Q96JM8; Q96MS9; Q9BVF3; Q9NX87
Background:
Focadhesin plays a crucial role in maintaining proteostatic levels of SKIC2 and SKIC3 in the liver, indicating its significant involvement in cellular homeostasis. Additionally, it is implicated in the regulation of RNA degradation, showcasing its potential impact on gene expression and cellular function.
Therapeutic significance:
Given its association with severe congenital liver disease, focadhesin's study offers a promising avenue for developing targeted therapies aimed at mitigating hepatic dysfunction and improving patient outcomes.